Development of Coactivator-Dependent, First-in-Class Therapies for Breast Cancer
Annual rept. 15 Aug 2013-14 Aug 2014
BAYLOR COLL OF MEDICINE HOUSTON TX
Pagination or Media Count:
By integrating multiple signaling pathways that cancer cells rely on for growth and survival, p160 steroid receptor coactivator SRC family members SRC-1, SRC-2TIF2GRIP1, SRC- 3AIB1pCIPRAC3 represent emerging targets for anti-cancer drug development. During this reporting period, we have characterized and published our work on two potent and selective small molecule inhibitors SMIs, bufalin and verrucarin A, against SRCs from high throughput screening efforts. Cryo-electron microscopic analyses of DNAestrogen receptorSRC-3 protein complexes achieved by our group are providing powerful new insights into understanding the conformation of intact, full length proteins in a complex and should provide valuable new information on the mechanism of action of SRC SMIs as well.
- Anatomy and Physiology
- Medicine and Medical Research
- Organic Chemistry